All News
Video: Psoriatic Arthritis Highlights from #EULAR2021 Dr. Jack Cush
https://t.co/xedmiZKOd5 https://t.co/AShEze5rFy
Links:
Dr. John Cush RheumNow ( View Tweet)
Find our #EULAR2021 psoriatic arthritis coverage in one place.
https://t.co/NzB2e2Vfwb https://t.co/P8TfUxfA3F
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush reviews highlight presentations from Virtual #EULAR2021.
https://t.co/yjId7QNRRR
Links:
Dr. John Cush RheumNow ( View Tweet)
Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis by Dr. Meral K El Ramahi (@MeralElRamahiMD ) #EULAR2021
https://t.co/l6YnJvuPdi
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Video: Personalization of PsA Treatment: Dr. Robert Chao (@doctorRBC ) #EULAR2021
https://t.co/7FmZ4BzHwp
Links:
Dr. John Cush RheumNow ( View Tweet)
Combination vs. Sequential Therapy for the Treatment of Lupus Nephritis by Dr. Kathryn Dao ( @KDAO2011 )
#EULAR2021
https://t.co/0d1bxBlUS0
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: How Can We Help our Patients with Sjogren's? Dr. Janet Pope (@Janetbirdope ) #EULAR2021
https://t.co/dHIrEBs1Rc
Links:
Dr. John Cush RheumNow ( View Tweet)
Artificial intelligence brings clarity to early bony changes in inflammatory arthritis by Dr. David Liew
https://t.co/RPH3k2Gz0W
#EULAR2021
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
POS0192
BL prognostic factors of achieving MDA in 77 early PsA treated #T2T strategy.
See forest plot below. Rather sobering results. It seems nearly fullfilling MDA at baseline is associated with fullfilling MDA at 12 months.
More useful predictors needed
#EULAR2021 @RheumNow https://t.co/7U65Nt3Woj
Paul Studenic Stiddyo ( View Tweet)
How common is #burnout among rheumatologists? Dr Maldonado surveyed N=297 in Latin America using Maslach Burnout Inventory. 57% had burnout. Associated with younger,long hours,⬇️satisfaction, depression,⬇️wage,comorbidities. Let's support each other #EULAR2021 #POS0302 @RheumNow https://t.co/QOA2xsDZen
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2021 POS1019
What does remission mean in AxSpA?
Physician's perception impacted most by:
⭐️Morning stiffness
⭐️Axial pain
⭐️NSAID use
⭐️Extra-artic manif
❌Fatigue less impact
Many subjective factors w/o consensus in AxSpA
@RheumNow
Eric Dein ejdein1 ( View Tweet)
Looking for all #EULAR2021 JAK/TYK2 coverage? We've got it all in one place on RheumNow.
https://t.co/6diCyfyJxI https://t.co/p26PU77aAm https://t.co/VYijM3X2aL
Dr. John Cush RheumNow ( View Tweet)
Are We Consistent in Making a SpA Diagnosis? Dr. Eric Dein ( @ejdein1 ) #EULAR2021
https://t.co/yuer9njuTe https://t.co/gBQ6qwkxvo
Links:
Dr. John Cush RheumNow ( View Tweet)
Attention bosses!
AxSpA patients who were older and worse disease activity associated with more sick leave
⭐️male gender and higher education associated with less sick leave
Abs#POS0238
#EULAR2021 @RheumNow https://t.co/aSs0BCHjau
Robert B Chao, MD doctorRBC ( View Tweet)
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Links:
Dr. John Cush RheumNow ( View Tweet)
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptoTate )
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.
Read more.
https://t.co/AnHQGA8aKs https://t.co/yJbymc9csR
Links:
Dr. John Cush RheumNow ( View Tweet)
Caveats:
-secondary analysis (consider exploratory)
-unclear clinical significance (modest ΔeGFR)
-baseline CrCl 40+ (do NOT use in advanced CKD)
-systemic rheumatic diseases excluded (unethical to randomize to PBO for 2 years)
-generalizability (all had CVD, M>F, mean age 66)
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Results: MTX vs. PBO
✅Difference in least-squares mean ΔeGFR 0.93 mL/min/1.73m2 (p<0.001)
✅HR for kidney AE on safety labs: 0.73 (0.59-0.91)
✔️HR for kidney AE clinical events: 0.87 (0.56-1.36)
✔️4 vs. 8 severe kidney AEs (HR 0.50, 0.15-1.64)
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
